Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
133
datasets available to search
ShareScore release 0.9.0
Dataset results
133 results for “age-related macular degeneration (AMD)”
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
ClinicalTrials.gov study NCT05893537. IPD Sharing: NO. Countries: 1. Publications: 0.
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT03815825. IPD Sharing: NO. Countries: 9. Publications: 1.
EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
ClinicalTrials.gov study NCT01756248. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Lutein-enriched-egg Beverage on Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00902408. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT01327222. IPD Sharing: Not stated. Countries: 1. Publications: 2.
TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
ClinicalTrials.gov study NCT03675880. IPD Sharing: NO. Countries: 1. Publications: 9.
The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study
ClinicalTrials.gov study NCT00599222. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT02395757. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
ClinicalTrials.gov study NCT00987129. IPD Sharing: Not stated. Countries: 1. Publications: 7.
A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00363714. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00090623. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT01301443. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT01217762. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)
ClinicalTrials.gov study NCT03668054. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00078221. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT01024998. IPD Sharing: Not stated. Countries: 1. Publications: 1.
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00470678. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Data from: The Moorfields AMD database report 2 - fellow eye involvement with neovascular age-related macular degeneration
<p><b>Background/Aims:</b> Neovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on 'fellow eyes'' have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) anti-vascular endothelial growth factor treatment and timelines for fellow eye involvement.</p> <p><b>Methods:</b> Retrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients /120,286 single entries with data extracted between October 21, 2008 and August 9, 2018. The dataset for analysis consisted of 1180 sequential, 807 nonsequential, and 3410 unilateral eyes.</p> <p><b>Results: </b>Mean VA (Early Treatment Diabetic Retinopathy Study letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over two years lower (0.37±14), and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at two years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at two years, and median time interval to fellow eye involvement was 71 (IQR 27-147) weeks.</p> <p><b>Conclusion:</b> This report shows sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.</p>
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
ClinicalTrials.gov study NCT01722045. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00407719. IPD Sharing: Not stated. Countries: 0. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.